ClinicalTrials.gg
CompletedNCT07428525Updated Mar 11, 2026

A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function

A Phase 1 interventional study of AMG 133 in Hepatic Impairment, sponsored by Amgen. Completed at 5 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Mar 2025, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 368 studies in Liver Diseases with a site in United States — 45 open to participants now, 59 under way, 5 of them phase 3. Liver Diseases · United States.

Enrollment
152nd of 269
36 · median 48
Started
2025
with 9 others
Phase 1
62 of 368
4 open now
Registered
360th of 368
by date

Among the 368 studies in Liver Diseases with a site in United States, this one is the 152nd largest by enrollment of the 269 interventional ones that give a count, is one of 10 that started in 2025, is one of 62 in phase 1, and was the 360th registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

45 of the 368 studies in Liver Diseases with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 368 studies in Liver Diseases with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the trial is to evaluate the pharmacokinetics (PK) of AMG 133 after a single subcutaneous (SC) dose in participants with mild, moderate, or severe hepatic impairment compared to participants with normal hepatic function.

03

Conditions studied

  • Hepatic Impairment

Browse trials for

Keywords

  • Liver disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults 18 to 75 years of age, male or female.
  2. ≥ 22 kg/m\^2 at screening.
  3. For participants with normal hepatic function:

    • In good health with no findings from medical history, physical exam, (ECG), vital signs, or laboratory tests.
    • Systolic blood pressure (BP) 90-150 mmHg and diastolic BP 50-100 mmHg; pulse 40-110 bpm.
    • Stable body weight (\< 5 kg change) and no recent dietary modifications within 3 months.
  4. For participants with hepatic impairment:

    • Documented Class A (mild), B (moderate), or C (severe) hepatic impairment.
    • Clinically stable chronic liver disease (e.g., cirrhosis, , alcoholic liver disease, or stable ).
    • Systolic BP ≤ 170 mmHg and diastolic BP ≤ 100 mmHg.
  5. Willing to use reliable (if of ) or practice abstinence through 16 weeks after dosing.

Exclusion criteria

Exclusion Criteria:

  1. Any unstable medical condition (e.g., recent hospitalization or major surgery).
  2. History of acute or chronic pancreatitis within 1 year or lipase/amylase > 2× at screening.
  3. Endocrine disorder that can cause obesity (e.g., Cushing's syndrome).
  4. Significant cardiac conditions (e.g., arrhythmias, 2nd/3rd-degree AV block, Corrected Using Fridericia's Formula (QTcF) >450 msec men / >470 msec women for normal hepatic group; > 490 msec men / > 500 msec women for hepatic impairment).
  5. Estimated \< 60 mL/min/1.73 m\^2 (normal/mild) or \< 50 mL/min/1.73 m\^2 (moderate/severe impairment).
  6. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
  7. Uncontrolled thyroid disease or clinically significant gastroparesis.
  8. Prior bariatric surgery within 6 months.
  9. Poor venous access.
  10. Positive (HIV) test.
  11. to AMG 133 or its components.
  12. Current use of GLP-1 or GIP receptor agents within 3 months.
  13. Pregnancy or lactation, or unwillingness to follow requirements.
  14. History of substance or alcohol abuse within 1 year or current alcohol intake > 21 units/week (men) or > 14 units/week (women).
  15. Positive test for surface antigen or active (with unstable disease).
  16. Diabetes mellitus not meeting glycemic cutoffs ( ≥ 6.5 % for normal hepatic group or > 11 % for hepatic impairment group).
  17. Active (within 18 months for hepatic impairment group; within 5 years for normal hepatic group).
  18. Hepatic encephalopathy Grade ≥ 3 (uncontrolled) or severe uncontrolled ascites.
  19. Organ transplant recipients or those on .
  20. Participation in another clinical trial within 30 days or 5 drug half-lives (whichever is longer).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Group 1, AMG 133: Normal Hepatic Function (No Impairment)

    Participants with normal hepatic function will receive a single dose of AMG 133 SC on Day 1.

    Drug: AMG 133

  • Experimental
    Group 2, AMG-133: Child-Pugh A (Mild Hepatic Impairment)

    Participants with mild hepatic impairment will receive a single dose of AMG 133 SC on Day 1.

    Drug: AMG 133

  • Experimental
    Group 3, AMG-133: Child-Pugh B (Moderate Hepatic Impairment)

    Participants with moderate hepatic impairment will receive a single dose of AMG 133 SC on Day 1.

    Drug: AMG 133

  • Experimental
    Group 4, AMG-133: Child-Pugh C (Severe Hepatic Impairment)

    Participants with severe hepatic impairment will receive a single dose of AMG 133 SC on Day 1.

    Drug: AMG 133

Interventions

  • Participants will receive AMG 133 SC.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of AMG 133

    Time frame: Up to Day 120

  2. Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUClast) of AMG 133

    Time frame: Up to Day 120

  3. AUC from Time Zero to Infinity (AUCinf) of AMG 133

    Time frame: Up to Day 120

Secondary outcomes

  1. Number of Participants Who Experience Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to Day 120

  2. Number of Participants Who Experience Serious Adverse Events (SAEs)

    Time frame: Up to Day 120

  3. Number of Participants Who Develop Anti-AMG 133 Antibodies

    Time frame: Up to Day 120

07

Study locations

5 sites
  • Clinical Pharmacology Of Miami, LLC
    Miami, Florida 33172, United States
  • Panax Clinical Research
    Miami Lakes, Florida 33014-2811, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • The Texas Liver Institute, Inc.
    San Antonio, Texas 78215-2100, United States
  • Pinnacle Clinical Research San Antonio
    San Antonio, Texas 78229-4801, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Feb 2026, 11 months.

Of 48 industry-sponsored phase 1 interventional studies under Liver Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 11 months is below that.

Counting every sponsor, half of 53 studies reached it within 14 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2026
First posted
Feb 23, 2026
StartActual
Mar 14, 2025
Primary completionActual
Feb 26, 2026
CompletionActual
Feb 26, 2026
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07428525
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Feb 23, 2026
Start date
Mar 14, 2025
Primary completion
Feb 26, 2026
Completion
Feb 26, 2026
Last update
Mar 11, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maridebart cafraglutide

Start the discussion